30 closest matches · ranked by relevance
Puberty, Precocious
Primary: Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females) — 81.8; 80.9; 87.8; 82.8…
Precocious Puberty, Central
Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone at 6 Months. — 54 Participants
Central Precocious Puberty
Primary: Percentage of Participants With Peak Luteinizing Hormone (LH) Suppression in Gonadotropin-Releasing Hormone (GnRH) Stimulation at Week 24 — 97.47 percentage of…
Puberty, Precocious
Primary: Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6 — 76.2; 80.7; 90.5; 100 Percentage of…
Precocious · Leuprolide Acetate · Luteinizing Hormone (LH)
Primary: Percentage of Participants With Suppression of Peak-Stimulated Luteinizing Hormone — 96.9; 100.0; 93.8; 100.0 percentage of participants
Central Precocious Puberty
Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression — 100 percentage of participants
Central Precocious Puberty
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 252 participants
Central Precocious Puberty
Primary: Luteinizing Hormone (LH) — 0.88; 0.53; 0.07; 0.50 MIU/ML
Central Precocious Puberty
Primary: Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) During Enantone Treatment Phase — 4; 71; 0; 2 Participants
Precocious Puberty
Primary: Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L — 31; 6; 31; 3 participants
Precocious Puberty
Primary: Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and…
Central Precocious Puberty
Primary: Percentage of Participants With Luteinising Hormone (LH) Suppression After Gonadotropin-Releasing Hormone (GnRH) Stimulation — 100 percentage of participants
Central Precocious Puberty (CPP)
Primary: Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24…
Central Precocious Puberty
Primary: Percentage of Children With Luteinizing Hormone (LH) Suppression to Prepubertal Levels 30 Minutes After Leuprolide Stimulation at Month 6 — 93.18 percentage of…
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Puberty
Primary: Pubertal Onset — 9.86; 9.86; 11.66; 11.66 years
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Idiopathic Short Stature (ISS)
Primary: Number of Participants With One or More Drug-related Adverse Events — 42; 38; 11; 9 participants
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
Obesity · Insulin Resistance · Gonadal Dysfunction
Primary: Insulin Sensitivity — 8.559; 3.425; 3.756; 2.985 x10-4/min-1/mIU/mL
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Puberty, Precocious · McCune-Albright Syndrome
Primary: Change in Frequency of Annualized Days of Vaginal Bleeding on Treatment Compared to Baseline — -3.6 Days per year
Congenital Adrenal Hyperplasia (CAH)
Primary: Adult Height Relative to General Population — -0.34; -0.6 Standard Deviation Score (SDS) units
Growth Disorders · Intrauterine Growth Retardation
Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Systemic Lupus Erythematosus
Primary: Dose of Triptorelin for Ovarian Suppression — NA; 120 μg/kg
Idiopathic Short Stature
Primary: Change in Height — 14; 17.1; 18.9 Centimeters — p=<0.006
Adrenal Insufficiency · Excess Androgen · Congenital Adrenal Hyperplasia (CAH)
Primary: Number of Patients With 17-OHP Levels Equal or Below 1,200 ng/dL at 0700 — 0 Participants
Turner Syndrome
Primary: Total Brain Volume — 18.22; 19.78 percentage change